# Context Therapeutics Inc. (CNTX) — delisting/forced [announced]
Source: SEC API (secapi.ai) · situation sit_67d312e4830ca79d313c · retrieved 2026-08-12T21:22:19.718Z

## Overview
Overview We are a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies ("bsAb") for solid tumors.

On July 29, 2026, Context Therapeutics Inc. received written notice from the Nasdaq Listing Qualifications Department that the company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Rule) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has an initial 180 calendar day period, or until January 25, 2027, to regain compliance. If the bid price closes at $1.00 per share or more for a minimum of 10 consecutive business days by that date, Nasdaq will notify the company that it has achieved compliance. If the company does not regain compliance by January 25, 2027, it may be eligible for an additional 180-day compliance period (the Second Compliance Period) if it meets applicable market value and other listing standards for the Nasdaq Capital Market.

## Terms
- Counterparty: Nasdaq Stock Market LLC · Price/share: $1

## Key dates
- Announced 2026-07-31 · Expiry 2027-01-25

## Timeline
- 2026-07-31 · 8-K (0001628280-26-051399): 8-K - Context Therapeutics Inc. — *Overview We are a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies ("bsAb") for solid tumors.* On July 29, 2026, Context Therapeutics Inc. received written notice from the Nasdaq Listing Qualifications Department that the company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Rule) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has an initial 180 calendar day period, or until January 25, 2027, to regain compliance. If the bid price closes at $1.00 per share or more for a minimum of 10 consecutive business days by that date, Nasdaq will notify the company that it has achieved compliance. If the company does not regain compliance by January 25, 2027, it may be eligible for an additional 180-day compliance period (the Second Compliance Period) if it meets applicable market value and other listing standards for the Nasdaq Capital Market.
  https://www.sec.gov/Archives/edgar/data/1842952/0001628280-26-051399.txt

## Citations
- 0001628280-26-051399 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000162828026051399